GEN Exclusives

More »

Feature Articles

More »
Oct 1, 2011 (Vol. 31, No. 17)

Creating Modern Industrial Microbiology

Combination of Fermentation, Genetics, and Biotechnology Produced a Formidable Force

  • Metabolic Engineering

    The improvement of product formation or cellular properties via modification of specific biochemical reactions or the introduction of new properties with the use of recombinant DNA technology is known as metabolic engineering. Analytical methods are combined to quantify fluxes and to control them with molecular biological techniques in order to implement suggested genetic modifications.

    The overall flux through a metabolic pathway depends on several steps, not just a single rate-limiting reaction. Amino acid production is one of the fields with many examples of this approach.

    Reverse (inverse) metabolic engineering is another technique that involves choosing a strain that has a favorable cellular phenotype, evaluating and determinating the genetic and/or environmental factors that confer that phenotype, and finally, transferring that phenotype to a second strain via direct modifications of the identified genetic and/or environmental factors.

    Molecular breeding techniques are based on mimicking natural recombination by in vitro homologous recombination. DNA shuffling not only recombines DNA fragments but also introduces point mutations at a very low controlled rate. Unlike site-directed mutagenesis, this method of pooling and recombining parts of similar genes from different species or strains has yielded remarkable improvements in a short amount of time.

    Whole-genome shuffling is another technique that combines the advantage of multiparental crossing allowed by DNA shuffling with the recombination of entire genomes through recursive protoplast fusion.

  • Systems Biology

    Systems biology is an integrated, systemic approach to the analysis and optimization of cellular processes by introducing a variety of perturbations and then measuring the system response. Altered phenotypes are created by molecular biological techniques or by altering environments. Further characterization of the phenotype leading to maximal product formation is analyzed and quantified through the use of genome-wide high-throughput omics data and genome-scale computational analysis.

    Secondary metabolites are a group that includes antibiotics, pesticides, pigments, toxins, pheromones, enzyme inhibitors, immunomodulating agents, receptor antagonists and agonists, pesticides, antitumor agents, immunosuppresants, cholesterol-lowering agents, plant protectants and animal and plant growth factors—these metabolites have tremendous economic importance. This remarkable group of compounds is produced by certain restricted taxonomic groups of organisms and usually formed as mixtures of closely related members of a chemical family.

    The antibiotics include β-lactams (penicillins, cephalosporins, cephamycins, clavulanic acid, and carbapenems), aminoglycosides, macrolides (erythromycin, oleandomycin, pikromycin, tylosin and amphotericin B), and polyenes.

    Metabolic engineering has been used to replace the normal promoter to increase antibiotic production many-fold. High-level expression of positive regulatory genes has led to major increases in antibiotic production.

    The production of antibiotics in heterologous hosts via combinatorial biosynthesis is becoming popular in antibiotic production and discovery. Over 200 new polyketides have been made by combinatorial biosynthesis, which also has been used to construct macrolides with new sugar moieties.

    An important new strategy to improve the discovery of new antibiotics is genome mining, which has come about due to advances in microbial genomics. Mining of whole-genome sequences and genome scanning allows the rapid identification of more than 450 clusters of genes (in antibiotic-producing cultures) that encode the biosynthesis of new bioactive products. Genome mining also allows one to predict structure based on gene sequences.

    Research in this area includes mining of whole-genome sequences, genome scanning, and heterologous expression. The discovery of novel chemistry has also been a result. Genomics could provide a huge group of new targets against which natural products can be screened.

    Biopharmaceutical products, a key part of the pharmaceutical industry, are biotechnology’s major contribution. These products can be categorized into four major groups: protein therapeutics with enzymatic activity (e.g., insulin), protein vaccines, protein therapeutics with special targeting activity (e.g., monoclonal antibodies) and protein diagnostics (e.g., biomarkers).

    Biologics accounted for over $80 billion in sales in 2008. Six of these therapeutic proteins were among the best-selling drugs in the U.S. in that year. Monoclonal antibodies and Fc-fusion proteins made up 43% of this market value. The market reached over $90 billion in 2010.

  • Protein Therapeutics

    Genetic engineering allows the production of massive quantities of desired proteins. Protein quality, functionality, production speed, and yield are the most important factors to consider when choosing the right expression system for recombinant protein production.

    The major organisms used for protein production are mammalian cells (mainly CHO cells) and E. coli. CHO cells constitute the preferred system for producing monoclonal antibodies and some other recombinant proteins. By 2006, production of therapeutic proteins by mammalian systems reached $20 billion.

    A relatively new system is PER.C6, which has been reported to produce 27 g/L of a monoclonal antibody.

    Some recombinant proteins are also made by yeasts (Saccharomyces cerevisiae, Pichia pastoris), molds, insect cells, plant cells, transgenic plants, and transgenic animals. Some fungi such as Chrysosporium lucknowense can make native protein at a level of 100 g/L. It has been genetically converted into a nonfilamentous, less viscous, low protease-producing strain that is capable of producing high yields of heterologous proteins.

    Directed evolution of proteins includes DNA shuffling, whole-genome shuffling, heteroduplex, random chimeragenesis of transient templates, assembly of designed oligonucleotides, mutagenic and unidirectional reassembly, exon shuffling, Y-ligation–based block shuffling, nonhomologous recombination, and the combining of rational design with directed evolution. Application of such technologies have led to protein titers of 5–10 g/L. Indeed, claims have been made that P. pastoris can make 20–30 g/L of recombinant proteins.

    The properties of many enzymes modified by genetic approaches including DNA shuffling, result from changes in substrate specificity, increased or modified enantioselectivity, resistance to feedback inhibition, kinetic parameters (Vmax, Km or Ki), pH optimum, thermostability, stability in organic solvents, and increased biological activity.

    The best is yet to come from the combination of industrial microbiology and recombinant DNA technology. Many of the new techniques are carried out by small companies and academic groups that could play a major role in rescuing us from the antibiotic crisis that we are now experiencing.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?